Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Herstal – page 63

1 407 clinical trials in Herstal, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Herstal at a glance
1 407
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 407 trials in Herstal

Open in trial search

Vitiligo

Not recruiting

Study of ritlecitinib (50 mg and 100 mg daily) compared to placebo in adults with nonsegmental vitiligo

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Pfizer Inc.

Vitiligo

Not recruiting

Study on the Effects of Upadacitinib in Adults and Adolescents with Non-Segmental Vitiligo Eligible for Systemic Treatment

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study of Oral Ozanimod as Maintenance Treatment for Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ozanimod
  • Sponsor:Celgene International II S.a.r.l.

Vitiligo

Not recruiting

Study on the Effectiveness of Povorcitinib for Adults with Nonsegmental Vitiligo

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Dyslipidaemia

Not recruiting

Study of Evolocumab to Prevent Heart Disease Events in High-Risk Patients Without Previous Heart Attack or Stroke

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Evolocumab
  • Sponsor:Amgen Inc.

Dermatomyositis

Not recruiting

Study on the Effects of Human Normal Immunoglobulin in Adults with Dermatomyositis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Study of resmetirom (MGL-3196) in patients with Non-Alcoholic Steatohepatitis (NASH) to prevent liver damage and disease progression

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Resmetirom
  • Sponsor:Madrigal Pharmaceuticals Inc.

Study on the Effects of AR1001 (Mirodenafil Dihydrochloride) for Patients with Early Alzheimer's Disease

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Mirodenafil Dihydrochloride
  • Sponsor:Aribio Co. Ltd.

Crohn's disease

Not recruiting

Study on the Long-Term Safety and Efficacy of Oral Ozanimod for Patients with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Ozanimod
  • Sponsor:Celgene International II S.a.r.l.

Colitis ulcerative+1

Not recruiting

Study on the Effects of TEV-48574 for Adults with Moderate to Severe Ulcerative Colitis or Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Chronic kidney disease+1

Not recruiting

Study on Baxdrostat and Dapagliflozin for Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Herstal

What the registry says about research in the country

01 Immune System Diseases

Clinical research in Herstal is focused on immune system diseases, with all currently listed studies centered on atopic dermatitis. These trials are examining whether a new treatment approach can better control symptoms and improve everyday skin health for people living with moderate-to-severe disease.

  • Testing a new therapy for better control of atopic dermatitis
  • Comparing treatment effectiveness against placebo
  • Assessing improvements in skin signs and symptom severity

The research program in this Belgian city is aimed at understanding how well treatment options work for patients who need stronger support than standard care alone.

02 Atopic Dermatitis

The main disease under study is atopic dermatitis, a chronic inflammatory skin condition that can cause itching, redness, and discomfort. Current trials are looking at whether a targeted therapy can offer meaningful relief, either on its own or alongside common skin treatments.

  • Evaluating a new option for moderate-to-severe atopic dermatitis
  • Studying treatment used with topical corticosteroids and topical calcineurin inhibitors
  • Measuring changes in disease control and visible skin improvement
  • Supportive research for patients seeking better symptom management

These studies are designed to help clarify whether newer approaches can improve outcomes for people whose skin disease remains difficult to manage.

03 Topical Combination Treatment Research

Another important area of research is the use of topical corticosteroids and topical calcineurin inhibitors alongside investigational therapy. This work is focused on evaluating how combination treatment may improve relief and disease control compared with standard topical care alone.

  • Studying combination care for moderate-to-severe atopic dermatitis
  • Assessing whether added therapy improves overall response
  • Looking at clinical signs and severity over time

The trials in Belgium reflect a practical clinical question: whether pairing new and established treatments can lead to better outcomes for patients.

04 Therapeutic Innovation in Skin Inflammation

The local trial landscape is small but concentrated, with all active studies exploring a single inflammatory skin condition. This makes Herstal a focused site for research on newer therapies aimed at reducing the burden of persistent eczema symptoms.

  • Exploring a new treatment for inflammatory skin disease
  • Comparing benefit against standard control approaches
  • Helping define better options for routine patient care

Overall, the studies are centered on improving treatment effectiveness and expanding options for people living with difficult-to-treat skin inflammation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.